Publications

• Delayed low-dose oral administration of 4'-fluorouridine inhibits pathogenic arenaviruses in animal models of lethal disease.
  Sci Transl Med Volume: 16 Page(s): eado7034
  11/20/2024 Authors: Welch SR; Spengler JR; Westover JB; Bailey KW; Davies KA; Aida-Ficken V; Bluemling GR; Boardman KM; Wasson SR; Mao S
• Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models.
  Nat Commun Volume: 14 Page(s): 4731
  08/07/2023 Authors: Cox RM; Lieber CM; Wolf JD; Karimi A; Lieberman NAP; Sticher ZM; Roychoudhury P; Andrews MK; Krueger RE; Natchus MG
• 4'-Fluorouridine mitigates lethal infection with pandemic human and highly pathogenic avian influenza viruses.
  PLoS Pathog Volume: 19 Page(s): e1011342
  04/01/2023 Authors: Lieber CM; Aggarwal M; Yoon J-J; Cox RM; Kang H-J; Sourimant J; Toots M; Johnson SK; Jones CA; Sticher ZM
• The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N4-Hydroxycytidine (EIDD-1931) in a mouse model of lethal Ebola virus infection.
  Antiviral Res Volume: 209 Page(s): 105453
  01/01/2023 Authors: Bluemling GR; Mao S; Natchus MG; Painter W; Mulangu S; Lockwood M; De La Rosa A; Brasel T; Comer JE; Freiberg AN
• SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model.
  Nat Commun Volume: 13 Page(s): 4416
  07/29/2022 Authors: Lieber CM; Cox RM; Sourimant J; Wolf JD; Juergens K; Phung Q; Saindane MT; Smith MK; Sticher ZM; Kalykhalov AA
• 4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication.
  Science Volume: 375 Page(s): 161 - 167
  01/14/2022 Authors: Sourimant J; Lieber CM; Aggarwal M; Cox RM; Wolf JD; Yoon J-J; Toots M; Ye C; Sticher Z; Kolykhalov AA
• Letter to the Editor in Response to Zhou et al.
  J Infect Dis Volume: 224 Page(s): 1442 - 1443
  10/28/2021 Authors: Troth S; Butterton J; DeAnda CS; Escobar P; Grobler J; Hazuda D; Painter G
• Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19.
  Curr Opin Virol Volume: 50 Page(s): 17 - 22
  10/01/2021 Authors: Painter GR; Natchus MG; Cohen O; Holman W; Painter WP
• Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2.
  Trials Volume: 22 Page(s): 561
  08/23/2021 Authors: Holman W; Holman W; McIntosh S; Painter W; Painter G; Bush J; Cohen O
• Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit.
  J Infect Dis Volume: 224 Page(s): S1 - S21
  07/15/2021 Authors: Hall MD; Anderson JM; Anderson A; Baker D; Bradner J; Brimacombe KR; Campbell EA; Corbett KS; Carter K; Cherry S
• Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2.
  Antimicrob Agents Chemother Volume: 65
  05/01/2021 Authors: Painter WP; Holman W; Bush JA; Almazedi F; Malik H; Eraut NCJE; Morin MJ; Szewczyk LJ; Painter GR
• SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801.
  Nature Volume: 591 Page(s): 451 - 457
  03/01/2021 Authors: Wahl A; Gralinski LE; Johnson CE; Yao W; Kovarova M; Dinnon KH; Liu H; Madden VJ; Krzystek HM; De C
• An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
  Sci Transl Med Volume: 12
  04/29/2020 Authors: Sheahan TP; Sims AC; Zhou S; Graham RL; Pruijssers AJ; Agostini ML; Leist SR; Schfer A; Dinnon KH; Stevens LJ
• Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model.
  Transl Res Volume: 218 Page(s): 16 - 28
  04/01/2020 Authors: Toots M; Yoon J-J; Hart M; Natchus MG; Painter GR; Plemper RK
• Analysis of the Potential for N4-Hydroxycytidine To Inhibit Mitochondrial Replication and Function.
  Antimicrob Agents Chemother Volume: 64
  01/27/2020 Authors: Sticher ZM; Lu G; Mitchell DG; Marlow J; Moellering L; Bluemling GR; Guthrie DB; Natchus MG; Painter GR; Kolykhalov AA
• Small-Molecule Antiviral -d-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance.
  J Virol Volume: 93
  12/15/2019 Authors: Agostini ML; Pruijssers AJ; Chappell JD; Gribble J; Lu X; Andres EL; Bluemling GR; Lockwood MA; Sheahan TP; Sims AC
• The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection.
  Antiviral Res Volume: 171 Page(s): 104597
  11/01/2019 Authors: Painter GR; Bowen RA; Bluemling GR; DeBergh J; Edpuganti V; Gruddanti PR; Guthrie DB; Hager M; Kuiper DL; Lockwood MA
• Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia.
  Sci Transl Med Volume: 11
  10/23/2019 Authors: Toots M; Yoon J-J; Cox RM; Hart M; Sticher ZM; Makhsous N; Plesker R; Barrena AH; Reddy PG; Mitchell DG
• Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses.
  Antimicrob Agents Chemother Volume: 62
  08/01/2018 Authors: Yoon J-J; Toots M; Lee S; Lee M-E; Ludeke B; Luczo JM; Ganti K; Cox RM; Sticher ZM; Edpuganti V
• Academic Drug Development: The DRIVE Model.
  ACS Med Chem Lett Volume: 9 Page(s): 403 - 407
  05/10/2018 Authors: Liotta D; Painter G
• -d-N4-Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome.
  J Virol Volume: 92
  02/01/2018 Authors: Urakova N; Kuznetsova V; Crossman DK; Sokratian A; Guthrie DB; Kolykhalov AA; Lockwood MA; Natchus MG; Crowley MR; Painter GR
• Simple In Vitro Assay To Evaluate the Incorporation Efficiency of Ribonucleotide Analog 5'-Triphosphates into RNA by Human Mitochondrial DNA-Dependent RNA Polymerase.
  Antimicrob Agents Chemother Volume: 62
  02/01/2018 Authors: Lu G; Bluemling GR; Mao S; Hager M; Gurale BP; Collop P; Kuiper D; Sana K; Painter GR; De La Rosa A
• Analysis of Ribonucleotide 5'-Triphosphate Analogs as Potential Inhibitors of Zika Virus RNA-Dependent RNA Polymerase by Using Nonradioactive Polymerase Assays.
  Antimicrob Agents Chemother Volume: 61
  03/01/2017 Authors: Lu G; Bluemling GR; Collop P; Hager M; Kuiper D; Gurale BP; Painter GR; De La Rosa A; Kolykhalov AA
• Arrested development.
  Science Volume: 354 Page(s): 1111
  12/02/2016 Authors: Painter G
• Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems.
  Antiviral Res Volume: 136 Page(s): 9 - 18
  12/01/2016 Authors: Welch SR; Guerrero LW; Chakrabarti AK; McMullan LK; Flint M; Bluemling GR; Painter GR; Nichol ST; Spiropoulou CF; Albario CG
• Development of nucleoside analogs as broadly active antiviral agents
  Volume: 252
  08/20/2016 Authors: Painter G
• Consortia's critical role in developing medical countermeasures for re-emerging viral infections: a USA perspective.
  Future Virol Volume: 11 Page(s): 187 - 195
  03/01/2016 Authors: Everts M; Suto MJ; Painter GR; Whitley RJ
• Discovery and Development of the Anti-Human Immunodeficiency Virus Drug, Emtricitabine (Emtriva, FTC).
  Acc Chem Res Volume: 49 Page(s): 2091 - 2098
  01/01/2016 Authors: Liotta DC; Painter GR
• Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus.
  Antiviral Res Volume: 111 Page(s): 42 - 52
  11/01/2014 Authors: Parker S; Crump R; Foster S; Hartzler H; Hembrador E; Lanier ER; Painter G; Schriewer J; Trost LC; Buller RM
• An orally available, small-molecule polymerase inhibitor shows efficacy against a lethal morbillivirus infection in a large animal model.
  Sci Transl Med Volume: 6 Page(s): 232ra52
  04/16/2014 Authors: Krumm SA; Yan D; Hovingh ES; Evers TJ; Enkirch T; Reddy GP; Sun A; Saindane MT; Arrendale RF; Painter G
• Evolving therapies for the treatment of HCV viral hepatitis.
  ACS Med Chem Lett Volume: 5 Page(s): 212 - 213
  03/13/2014 Authors: Painter G
• Mericitabine and sofosbuvir are potent pan-serotypic inhibitors of Dengue virus
  Volume: 19 Page(s): A105 - A105
  01/01/2014 Authors: Bluemling GR; Saindane MT; Lockwood MA; Kuiper DL; Hager MW; Culver D; Lu G; Evers TJ; Katkam A; Marengo JR
• First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses.
  Antimicrob Agents Chemother Volume: 56 Page(s): 2726 - 2734
  05/01/2012 Authors: Painter W; Robertson A; Trost LC; Godkin S; Lampert B; Painter G
• Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox.
  Antiviral Res Volume: 94 Page(s): 44 - 53
  04/01/2012 Authors: Parker S; Chen NG; Foster S; Hartzler H; Hembrador E; Hruby D; Jordan R; Lanier R; Painter G; Painter W
• Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans.
  Viruses Volume: 3 Page(s): 63 - 82
  02/01/2011 Authors: Rice AD; Adams MM; Lampert B; Foster S; Robertson A; Painter G; Moyer RW
• Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans.
  Viruses Volume: 3 Page(s): 47 - 62
  01/01/2011 Authors: Rice AD; Adams MM; Wallace G; Burrage AM; Lindsey SF; Smith AJ; Swetnam D; Manning BR; Gray SA; Lampert B
• Development of CMX001 for the Treatment of Poxvirus Infections.
  Viruses Volume: 2 Page(s): 2740 - 2762
  12/01/2010 Authors: Lanier R; Trost L; Tippin T; Lampert B; Robertson A; Foster S; Rose M; Painter W; O'Mahony R; Almond M
• Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies.
  J Infect Dis Volume: 202 Page(s): 1492 - 1499
  11/15/2010 Authors: Quenelle DC; Lampert B; Collins DJ; Rice TL; Painter GR; Kern ER
• Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics.
  Viruses Volume: 2 Page(s): 1918 - 1932
  09/01/2010 Authors: Parker S; Siddiqui AM; Painter G; Schriewer J; Buller RM
• Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
  Antimicrob Agents Chemother Volume: 54 Page(s): 2901 - 2909
  07/01/2010 Authors: Lanier ER; Ptak RG; Lampert BM; Keilholz L; Hartman T; Buckheit RW; Mankowski MK; Osterling MC; Almond MR; Painter GR
• In Vitro Hepatic Metabolism of CMX001, a Lipid Conjugate of Cidofovir
  Volume: 41 Page(s): 149 - 150
  10/01/2009 Authors: Tippin TK; Almond MR; Painter GR; Lampert BM
• Combinations of 5-Iodo-4 '-thio-2 '-deoxyuridine and ST-246 or CMX001 Synergistically Inhibit Orthopoxvirus Replication In Vitro
  Volume: 82 Page(s): A33 - A34
  05/01/2009 Authors: Keith K; Sanders S; Tiwari K; Maddry J; Secrist J; Jordan R; Hruby D; Lanier R; Painter G; Kern E
• Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies.
  Virology Volume: 385 Page(s): 11 - 21
  03/01/2009 Authors: Parker S; Siddiqui AM; Oberle C; Hembrador E; Lanier R; Painter G; Robertson A; Buller RM
• Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model.
  Proc Natl Acad Sci U S A Volume: 105 Page(s): 7293 - 7297
  05/20/2008 Authors: Toth K; Spencer JF; Dhar D; Sagartz JE; Buller RML; Painter GR; Wold WSM
• Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.
  Antivir Ther Volume: 13 Page(s): 863 - 873
  01/01/2008 Authors: Parker S; Schriewer J; Oberle C; Robertson A; Lanier R; Painter G; Buller RM
• Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model.
  Antiviral Res Volume: 77 Page(s): 39 - 49
  01/01/2008 Authors: Parker S; Touchette E; Oberle C; Almond M; Robertson A; Trost LC; Lampert B; Painter G; Buller RM
• Hexadecyloxypropyl tenofovir (CMX157) has enhanced potency in vitro against NRTI-resistant HIV relative to tenofovir and a favourable preclinical profile
  Volume: 13 Page(s): A6 - A6
  01/01/2008 Authors: Lanier ER; Lampert B; Trost L; Painter G; Almond M
• Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
  Antimicrob Agents Chemother Volume: 51 Page(s): 4118 - 4124
  11/01/2007 Authors: Quenelle DC; Prichard MN; Keith KA; Hruby DE; Jordan R; Painter GR; Robertson A; Kern ER
• Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
  Antimicrob Agents Chemother Volume: 51 Page(s): 3505 - 3509
  10/01/2007 Authors: Painter GR; Almond MR; Trost LC; Lampert BM; Neyts J; De Clercq E; Korba BE; Aldern KA; Beadle JR; Hostetler KY
• Combinations of CMX-001 and ST-246 synergistically inhibit orthopoxvirus replication in vitro
  Volume: 74 Page(s): A79 - A80
  06/01/2007 Authors: Keith K; Kern E; Sanders S; Conley R; Jordan R; Hruby D; Painter G; Prichard M
• Preclinical and clinical development of the anti-HIV, anti-HBV oxathiolane nucleoside analog emtricitabine
  Frontiers in Viral Hepatitis Volume: 2003 Page(s): 451 - 484
  05/09/2007 Authors: Schinazi RF; Painter GR; Rimsky LT; Furman PA; Liotta DC; Quinn JB
• CMX052, an orally available lipid conjugate of foscarnet for the treatment of drug resistant HIV
  Volume: 70 Page(s): A59 - A59
  05/01/2006 Authors: Trost L; Lampert B; Frick L; Almond M; Painter G
• The challenges of developing an antiviral agent for the treatment of smallpox using the animal efficacy rule
  FUTURE VIROLOGY Volume: 1 Page(s): 173 - 179
  03/01/2006 Authors: Painter G; Buller M; Kern E; Huggins J; Moyer R; Painter W; Doucette M; Robertson A
• Design and development of oral drugs for the prophylaxis and treatment of smallpox infection.
  Trends Biotechnol Volume: 22 Page(s): 423 - 427
  08/01/2004 Authors: Painter GR; Hostetler KY
• Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase.
  Curr Top Med Chem Volume: 4 Page(s): 1035 - 1044
  01/01/2004 Authors: Painter GR; Almond MR; Mao S; Liotta DC
• Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney.
  Antiviral Res Volume: 59 Page(s): 163 - 171
  08/01/2003 Authors: Ciesla SL; Trahan J; Wan WB; Beadle JR; Aldern KA; Painter GR; Hostetler KY
• The phenylpropenamide derivative AT-130 inhibits HRV replication at viral encapsidation and packaging.
  Volume: 36 Page(s): 300A - 300A
  10/01/2002 Authors: Feld J; Colledge D; Sozzi V; Edwards R; Painter GR; Locarnini SA
• Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro.
  Antimicrob Agents Chemother Volume: 46 Page(s): 3057 - 3060
  09/01/2002 Authors: Delaney WE; Edwards R; Colledge D; Shaw T; Furman P; Painter G; Locarnini S
• Anabolic profile of the dioxolane nucleoside analogue DXG in human PBMC; Reversal of resistance by boosting 5 '-triphosphate levels.
  Volume: 53 Page(s): A37 - A37
  03/01/2002 Authors: Painter GR; St Claire R; Feng J; Borroto-Esoda K
• Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine.
  Antimicrob Agents Chemother Volume: 45 Page(s): 158 - 165
  01/01/2001 Authors: Furman PA; Jeffrey J; Kiefer LL; Feng JY; Anderson KS; Borroto-Esoda K; Hill E; Copeland WC; Chu CK; Sommadossi JP
• DAPD - Anti-HIV anti-HBV
  DRUGS OF THE FUTURE Volume: 25 Page(s): 454 - 461
  05/01/2000 Authors: Furman PA; Cleary D; Trost LC; Bigley JW; Painter GR
• An analysis of the catalytic cycle of HIV-1 reverse transcriptase: opportunities for chemotherapeutic intervention based on enzyme inhibition.
  Curr Pharm Des Volume: 6 Page(s): 547 - 567
  03/01/2000 Authors: Furman PA; Painter GR; Anderson KS
• Conformation and local environment of nucleotides bound to HIV type 1 reverse transcriptase (HIV-1 RT) in the ground state.
  Nucleosides Nucleotides Nucleic Acids Volume: 19 Page(s): 13 - 29
  01/01/2000 Authors: Painter GR; Andrews CW; Furman PA
• Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1.
  Antimicrob Agents Chemother Volume: 44 Page(s): 123 - 130
  01/01/2000 Authors: Szczech GM; Furman P; Painter GR; Barry DW; Borroto-Esoda K; Grizzle TB; Blum MR; Sommadossi J; Endoh R; Niwa T
• Efficacy of topical acyclovir monophosphate, acyclovir, or penciclovir in orofacial HSV-1 infections of mice and genital HSV-2 infections of guinea pigs.
  Nucleosides Nucleotides Nucleic Acids Volume: 19 Page(s): 501 - 513
  01/01/2000 Authors: Kern ER; Palmer J; Szczech G; Painter G; Hostetler KY
• DNA polymerase activity of hepatitis B virus particles: differential inhibition by L-enantiomers of nucleotide analogs.
  Antiviral Res Volume: 30 Page(s): 133 - 145
  05/01/1996 Authors: Davis MG; Wilson JE; VanDraanen NA; Miller WH; Freeman GA; Daluge SM; Boyd FL; Aulabaugh AE; Painter GR; Boone LR
• In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents.
  Antiviral Res Volume: 29 Page(s): 53 - 56
  01/01/1996 Authors: St Clair MH; Millard J; Rooney J; Tisdale M; Parry N; Sadler BM; Blum MR; Painter G
• Recombinant human immunodeficiency virus type 1 reverse transcriptase is heterogeneous.
  J Acquir Immune Defic Syndr Hum Retrovirol Volume: 11 Page(s): 20 - 30
  01/01/1996 Authors: Wilson JE; Wright LL; Martin JL; Haire SE; Ray PH; Painter GR; Furman PA
• Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy.
  J Infect Dis Volume: 172 Page(s): 1238 - 1245
  11/01/1995 Authors: Livington DJ; Pazhanisamy S; Porter DJ; Partaledis JA; Tung RD; Painter GR
• Evaluation of the potent anti-hepatitis B virus agent (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model.
  Antimicrob Agents Chemother Volume: 38 Page(s): 616 - 619
  03/01/1994 Authors: Condreay LD; Jansen RW; Powdrill TF; Johnson LC; Selleseth DW; Paff MT; Daluge SM; Painter GR; Furman PA; Ellis MN
• LOCAL PERTURBATION OF RECOMBINANT HIV-1 REVERSE-TRANSCRIPTASE BY UREA OCCURS PRIOR TO GLOBAL DENATURATION
  Volume: 66 Page(s): A181 - A181
  02/01/1994 Authors: WRIGHT LL; WILSON JE; MARTIN JL; HAIRE SE; RAY PH; PAINTER GR
• Structural and functional characterization of the HPV16 E7 protein expressed in bacteria.
  J Biol Chem Volume: 268 Page(s): 26018 - 26025
  12/05/1993 Authors: Pahel G; Aulabaugh A; Short SA; Barnes JA; Painter GR; Ray P; Phelps WC
• Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus.
  Antimicrob Agents Chemother Volume: 37 Page(s): 2285 - 2292
  11/01/1993 Authors: Frick LW; St John L; Taylor LC; Painter GR; Furman PA; Liotta DC; Furfine ES; Nelson DJ
• Identification of the nucleotide binding site of HIV-1 reverse transcriptase using dTTP as a photoaffinity label.
  Biochemistry Volume: 32 Page(s): 7630 - 7634
  08/03/1993 Authors: Cheng N; Merrill BM; Painter GR; Frick LW; Furman PA
• The 5'-triphosphates of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl]cytosine equally inhibit human immunodeficiency virus type 1 reverse transcriptase.
  Antimicrob Agents Chemother Volume: 37 Page(s): 1720 - 1722
  08/01/1993 Authors: Wilson JE; Martin JL; Borroto-Esoda K; Hopkins S; Painter G; Liotta DC; Furman PA
• A comparison of the conformations of the 5'-triphosphates of zidovudine (AZT) and thymidine bound to HIV-1 reverse transcriptase.
  Biochem Biophys Res Commun Volume: 191 Page(s): 1166 - 1171
  03/31/1993 Authors: Painter GR; Aulabaugh AE; Andrews CW
• Conformational changes induced in herpes simplex virus DNA polymerase upon DNA binding.
  Proc Natl Acad Sci U S A Volume: 90 Page(s): 1028 - 1032
  02/01/1993 Authors: Weisshart K; Kuo AA; Painter GR; Wright LL; Furman PA; Coen DM
• RECOMBINANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) REVERSE-TRANSCRIPTASE PRODUCES A MIXED POPULATION OF FOLDED PROTEINS
  Volume: 64 Page(s): A170 - A170
  02/01/1993 Authors: WILSON JE; WRIGHT LL; PAINTER GR; MARTIN JL; FURMAN PA
• The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.
  Antimicrob Agents Chemother Volume: 36 Page(s): 2686 - 2692
  12/01/1992 Authors: Furman PA; Davis M; Liotta DC; Paff M; Frick LW; Nelson DJ; Dornsife RE; Wurster JA; Wilson LJ; Fyfe JA
• Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.
  Antimicrob Agents Chemother Volume: 36 Page(s): 2423 - 2431
  11/01/1992 Authors: Schinazi RF; McMillan A; Cannon D; Mathis R; Lloyd RM; Peck A; Sommadossi JP; St Clair M; Wilson J; Furman PA
• Role of desolvation energy in the nonfacilitated membrane permeability of dideoxyribose analogs of thymidine.
  Mol Pharmacol Volume: 41 Page(s): 957 - 962
  05/01/1992 Authors: Wright LL; Painter GR
• Initial binding of 2'-deoxynucleoside 5'-triphosphates to human immunodeficiency virus type 1 reverse transcriptase.
  J Biol Chem Volume: 266 Page(s): 19362 - 19368
  10/15/1991 Authors: Painter GR; Wright LL; Hopkins S; Furman PA
• Substrate inhibition of the human immunodeficiency virus type 1 reverse transcriptase.
  Proc Natl Acad Sci U S A Volume: 88 Page(s): 6013 - 6017
  07/15/1991 Authors: Furman PA; Painter G; Wilson JE; Cheng N; Hopkins S
• Crosslinking of substrates occurs exclusively to the p66 subunit of heterodimeric HIV-1 reverse transcriptase.
  Biochem Biophys Res Commun Volume: 174 Page(s): 785 - 789
  01/31/1991 Authors: Cheng N; Painter GR; Furman PA
• The effects of lipid composition on the binding of lasalocid A to small unilamellar vesicles.
  Biochim Biophys Acta Volume: 1027 Page(s): 245 - 252
  09/07/1990 Authors: Grunwald R; Painter GR
• Carrier-independent entry of 1-methyl-4-phenylpyridinium (MPP+) into adrenal chromaffin cells as a consequence of charge delocalization.
  Biochem Biophys Res Commun Volume: 168 Page(s): 1143 - 1148
  05/16/1990 Authors: Reinhard JF; Daniels AJ; Painter GR
• Investigation of the stereochemical course of DNA synthesis catalysed by human immunodeficiency virus type 1 reverse transcriptase.
  Biochem Biophys Res Commun Volume: 163 Page(s): 106 - 110
  08/30/1989 Authors: Hopkins S; Furman PA; Painter GR
• 31P nuclear magnetic resonance study of the metabolic pools of adenosine triphosphate in cultured bovine adrenal medullary chromaffin cells.
  Proc Natl Acad Sci U S A Volume: 86 Page(s): 2239 - 2242
  04/01/1989 Authors: Painter GR; Diliberto EJ; Knoth J
• ANALYSIS OF THE H-1-NMR SPECTRA OF THE CARBOXYLIC IONOPHORE NARASIN-A IN ITS APO AND CATION-BOUND FORMS
  MAGNETIC RESONANCE IN CHEMISTRY Volume: 27 Page(s): 403 - 406
  04/01/1989 Authors: CAUGHEY BW; GIBBONS WA; PAINTER GR
• Accumulation of 1-methyl-4-phenylpyridinium (MPP+) into bovine chromaffin granules results in a large restriction of its molecular motion: a 13C and 31P NMR study.
  Biochem Biophys Res Commun Volume: 156 Page(s): 1243 - 1249
  11/15/1988 Authors: Daniels AJ; Reinhard JF; Painter GR
• Interaction of the antifolate antibiotic trimethoprim with phosphatidylcholine membranes: a 13C and 31P nuclear magnetic resonance study.
  Mol Pharmacol Volume: 33 Page(s): 551 - 558
  05/01/1988 Authors: Painter GR; Grunwald R; Roth B
• EFFECTS OF LIPID-COMPOSITION ON THE BINDING OF LASALOCID-A TO SMALL UNILAMELLAR PHOSPHOLIPID-VESICLES
  Volume: 53 Page(s): A255 - A255
  02/01/1988 Authors: GRUNWALD R; PORTER N; PAINTER G
• INTERACTION OF ARYLMETHYLAMINOPROPANEDIOLS (AMAPS) WITH VESICLE MEMBRANES - RELATIONSHIP OF MEMBRANE-BINDING TO LOCAL-ANESTHETIC ACTIVITY
  Volume: 28 Page(s): 270 - 270
  03/01/1987 Authors: PAINTER GR; BAIR KW; GRUNWALD R; WANG CM; TUTTLE RL
• Equilibrium cation binding selectivity of the carboxylic ionophore narasin A: a comparison with transport selectivities reported in two biological test systems.
  Biochem Pharmacol Volume: 35 Page(s): 4103 - 4105
  11/15/1986 Authors: Caughey B; Painter GR; Gibbons WA
• C-13 RELAXATION STUDIES OF THE STRUCTURE AND FLEXIBILITY OF THE CARBOXYLIC IONOPHORE LASALOCID-A
  JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2 Page(s): 1151 - 1154
  08/01/1986 Authors: PAINTER GR; GIBBONS WA
• The role of molecular conformation in ion capture by carboxylic ionophores: a circular dichroism study of narasin A in single-phase solvents and liposomes.
  Biochim Biophys Acta Volume: 854 Page(s): 109 - 116
  01/16/1986 Authors: Caughey B; Painter GR; Drake AF; Gibbons WA
• CATION COMPLEXES OF THE MONO-VALENT AND POLYVALENT CARBOXYLIC IONOPHORES - LASALOCID (X-537A), MONESIN, A23187 (CALCIMYCIN), AND RELATED ANTIBIOTICS
  METAL IONS IN BIOLOGICAL SYSTEMS Volume: 19 Page(s): 229 - 294
  01/01/1985 Authors: PAINTER GR; PRESSMAN BC
• THE PREPARATION AND REARRANGEMENT OF TRICHOTHECANE-LIKE COMPOUNDS - A SYNTHESIS OF APLYSIN AND FILIFORMIN
  Volume: 180 Page(s): 18 - ORGN
  01/01/1980 Authors: GOLDSMITH DJ; JOHN TK; KWONG CD; PAINTER GR